Skip to content
About Us
Pipeline
News
Investors
Contact Us
News
Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria
Learn More
Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Learn More
Cue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission
Learn More
